DNA methylation-based biomarkers in serum of patients with breast cancer

Mutation Research - Reviews in Mutation Research

Volumn 751, Issue 2, 2012, Pages 304-325

  Van De Voorde, Lien ^a   Speeckaert, Reinhart ^a   Van Gestel, Dirk ^b   Bracke, Marc ^a   De Neve, Wilfried ^a   Delanghe, Joris ^a   Speeckaert, Marijn ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Biomarker; Breast cancer; DNA methylation; Epigenetics

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5' FLUORO 2' DEOXYCYTIDINE; AZACITIDINE; BISULFITE; CP 4200; CYTIDINE DERIVATIVE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; UNCLASSIFIED DRUG; ZEBULARINE;

ALLELE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CELL CYCLE REGULATION; DEAMINATION; DISEASE MARKER; DNA METHYLATION; DNA MICROARRAY; DRUG TARGETING; ENZYME ASSAY; EPIGENETICS; GENETIC HETEROGENEITY; HIGH RISK PATIENT; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PYROSEQUENCING; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84865643124     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2012.06.001     Document Type: Review

References (230)

1. Hayes D.F., Isaacs C., Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J. Mammary Gland Biol. Neoplasia 2001, 6:375-392.
2. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3:253-266.
3. Radpour R., Barekati Z., Kohler C., Lv Q., Burki N., Diesch C., Bitzer J., Zheng H., Schmid S., Zhong X.Y. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One 2011, 6:e16080.
4. Hanash S.M., Baik C.S., Kallioniemi O. Emerging molecular biomarkers - blood- based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol. 2011, 8:142-150.
5. Kohler C., Barekati Z., Radpour R., Zhong X.Y. Cell-free DNA in the circulation as a potential cancer biomarker. Anticancer Res. 2011, 31:2623-2628.
6. Ignatiadis M., Reinholz M. Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res. 2011, 13:222.
7. Sharma V.K., Vauros P., Glick J. Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids. Int. J. Mass Spectrom. 2011, 304:172-183.
8. Anker P., Mulcahy H., Chen X.Q., Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev. 1999, 18:65-73.
9. Muller H.M., Widschwendter A., Fiegl H., Ivarsson L., Goebel G., Perkmann E., Marth C., Widschwendter M. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. 2003, 63:7641-7645.
10. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
11. Fabian C.J., Kimler B.F., Mayo M.S., Khan S.A. Breast-tissue sampling for risk assessment and prevention. Endocr. Relat. Cancer 2005, 12:185-213.
12. Jones P.A., Liang G. Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 2009, 10:805-811.
13. Wong E.M., Southey M.C., Fox S.B., Brown M.A., Dowty J.G., Jenkins M.A., Giles G.G., Hopper J.L., Dobrovic A. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev. Res. (Phila) 2011, 4:23-33.
14. Yan P.S., Venkataramu C., Ibrahim A., Liu J.C., Shen R.Z., Diaz N.M., Centeno B., Weber F., Leu Y.W., Shapiro C.L., Eng C., Yeatman T.J., Huang T.H. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin. Cancer Res. 2006, 12:6626-6636.
15. Zhu J., Yao X. Use of DNA methylation for cancer detection: promises and challenges. Int. J. Biochem. Cell Biol. 2009, 41:147-154.
16. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
17. Hoque M.O., Prencipe M., Poeta M.L., Barbano R., Valori V.M., Copetti M., Gallo A.P., Brait M., Maiello E., Apicella A., Rossiello R., Zito F., Stefania T., Paradiso A., Carella M., Dallapiccola B., Murgo R., Carosi I., Bisceglia M., Fazio V.M., Sidransky D., Parrella P. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2694-2700.
18. Kristensen L.S., Nielsen H.M., Hansen L.L. Epigenetics and cancer treatment. Eur. J. Pharmacol. 2009, 625:131-142.
19. Yang X., Yan L., Davidson N.E. DNA methylation in breast cancer. Endocr. Relat. Cancer 2001, 8:115-127.
20. Jia D., Jurkowska R.Z., Zhang X., Jeltsch A., Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 2007, 449:248-251.
21. Van Emburgh B.O., Robertson K.D. Modulation of Dnmt3b function in vitro by interactions with Dnmt3L, Dnmt3a and Dnmt3b splice variants. Nucleic Acids Res. 2011, 39:4984-5002.
22. Veeck J., Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J. Mammary Gland Biol. Neoplasia 2010, 15:5-17.
23. Holz-Schietinger C., Reich N.O. The inherent processivity of the human de novo methyltransferase 3A (DNMT3A) is enhanced by DNMT3L. J. Biol. Chem. 2010, 285:29091-29100.
24. Robertson K.D., Uzvolgyi E., Liang G., Talmadge C., Sumegi J., Gonzales F.A., Jones P.A. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999, 27:2291-2298.
25. Mizuno S., Chijiwa T., Okamura T., Akashi K., Fukumaki Y., Niho Y., Sasaki H. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001, 97:1172-1179.
26. Gatto S., Della Ragione F., Cimmino A., Strazzullo M., Fabbri M., Mutarelli M., Ferraro L., Weisz A., D'Esposito M., Matarazzo M.R. Epigenetic alteration of microRNAs in DNMT3B-mutated patients of ICF syndrome. Epigenetics 2010, 5:427-443.
27. Hammons G.J., Yan Y., Lopatina N.G., Jin B., Wise C., Blann E.B., Poirier L.A., Kadlubar F.F., Lyn-Cook B.D. Increased expression of hepatic DNA methyltransferase in smokers. Cell Biol. Toxicol. 1999, 15:389-394.
28. Xiao Y., Word B., Starlard-Davenport A., Haefele A., Lyn-Cook B.D., Hammons G. Age and gender affect DNMT3a and DNMT3b expression in human liver. Cell Biol. Toxicol. 2008, 24:265-272.
29. Girault I., Tozlu S., Lidereau R., Bieche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin. Cancer Res. 2003, 9:4415-4422.
30. El-Maarri O., Kareta M.S., Mikeska T., Becker T., Diaz-Lacava A., Junen J., Nusgen N., Behne F., Wienker T., Waha A., Oldenburg J., Chedin F. A systematic search for DNA methyltransferase polymorphisms reveals a rare DNMT3L variant associated with subtelomeric hypomethylation. Hum. Mol. Genet. 2009, 18:1755-1768.
31. Taylor J., Moore H., Beaujean N., Gardner J., Wilmut I., Meehan R., Young L. Cloning and expression of sheep DNA methyltransferase 1 and its development-specific isoform. Mol. Reprod. Dev. 2009, 76:501-513.
32. Xiang G., Zhenkun F., Shuang C., Jie Z., Hua Z., Wei J., Da P., Dianjun L. Association of DNMT1 gene polymorphisms in exons with sporadic infiltrating ductal breast carcinoma among Chinese Han women in the Heilongjiang Province. Clin. Breast Cancer 2010, 10:373-377.
33. Montgomery K.G., Liu M.C., Eccles D.M., Campbell I.G. The DNMT3B C-->T promoter polymorphism and risk of breast cancer in a British population: a case-control study. Breast Cancer Res. 2004, 6:R390-R394.
34. Ye C., Beeghly-Fadiel A., Lu W., Long J., Shu X.O., Gao Y.T., Zheng W., Cai Q. Two-stage case-control study of DNMT-1 and DNMT-3B gene variants and breast cancer risk. Breast Cancer Res. Treat. 2010, 121:765-769.
35. Cebrian A., Pharoah P.D., Ahmed S., Ropero S., Fraga M.F., Smith P.L., Conroy D., Luben R., Perkins B., Easton D.F., Dunning A.M., Esteller M., Ponder B.A. Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 2006, 27:1661-1669.
36. Das P.M., Singal R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22:4632-4642.
37. Ziller M.J., Müller F., Liao J., Zhang Y., Gu H., Bock C., Boyle P., Epstein C.B., Bernstein B.E., Lengauer T., Gnirke A., Meissner A. Genomic distribution and inter-sample variation of non-CpG methylation across human cell types. PLoS Genet. 2011, 7:e1002389.
38. Ndlovu M.N., Denis H., Fuks F. Exposing the DNA methylome iceberg. Trends Biochem. Sci. 2011, 36:381-387.
39. Dedeurwaerder S., Fumagalli D., Fuks F. Unravelling the epigenomic dimension of breast cancers. Curr. Opin. Oncol. 2011, 23:559-565.
40. Lister R., Pelizzola M., Dowen R.H., Hawkins R.D., Hon G., Tonti-Filippini J., Nery J.R., Lee L., Ye Z., Ngo Q.M., Edsall L., Antosiewicz-Bourget J., Stewart R., Ruotti V., Millar A.H., Thomson J.A., Ren B., Ecker J.R. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462:315-322.
41. Brenet F., Moh M., Funk P., Feierstein E., Viale A.J., Socci N.D., Scandura J.M. DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One 2011, 6:e14524.
42. Baylin S.B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2005, 2(Suppl. 1):S4-S11.
43. Sidransky D. Emerging molecular markers of cancer. Nat. Rev. Cancer 2002, 2:210-219.
44. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997, 278:1054-1059.
45. Suijkerbuijk K.P., van Diest P.J., van der Wall E. Improving early breast cancer detection: focus on methylation. Ann. Oncol. 2011, 22:24-29.
46. Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., Winget M., Yasui Y. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 2001, 93:1054-1061.
47. Melnikov A.A., Gartenhaus R.B., Levenson A.S., Motchoulskaia N.A., Levenson Chernokhvostov V.V. MSRE-PCR for analysis of gene-specific DNA methylation. Nucleic Acids Res. 2005, 33:e93.
48. Rein T., Zorbas H., DePamphilis M.L. Active mammalian replication origins are associated with a high-density cluster of mCpG dinucleotides. Mol. Cell. Biol. 1997, 17:416-426.
49. Costello J.F., Smiraglia D.J., Plass C. Restriction landmark genome scanning. Methods 2002, 27:144-149.
50. Okuizumi H., Takamiya T., Okazaki Y., Hayashizaki Y. Restriction landmark genome scanning. Methods Mol. Biol. 2011, 791:101-112.
51. Frigola J., Ribas M., Risques R.A., Peinado M.A. Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic Acids Res. 2002, 30:e28.
52. Liang G., Chan M.F., Tomigahara Y., Tsai Y.C., Gonzales F.A., Li E., Laird P.W., Jones P.A. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol. Cell. Biol. 2002, 22:480-491.
53. Southern E., Mir K., Shchepinov M. Molecular interactions on microarrays. Nat. Genet. 1999, 21:5-9.
54. Huang T.H., Perry M.R., Laux D.E. Methylation profiling of CpG islands in human b reast cancer cells. Hum. Mol. Genet. 1999, 8:459-470.
55. Laird P.W. Principles and challenges of genomewide DNA methylation analysis. Nat. Rev. Genet. 2010, 11:191-203.
56. Irizarry R.A., Ladd-Acosta C., Carvalho B., Wu H., Brandenburg S.A., Jeddeloh J.A., Wen B., Feinberg A.P. Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res. 2008, 18:780-790.
57. Ibrahim A.E., Thorne N.P., Baird K., Barbosa-Morais N.L., Tavare S., Collins V.P., Wyllie A.H., Arends M.J., Brenton J.D. MMASS: an optimized array-based method for assessing CpG island methylation. Nucleic Acids Res. 2006, 34:e136.
58. Suzuki M., Greally J.M. DNA methylation profiling using HpaII tiny fragment enrichment by ligation-mediated PCR (HELP). Methods 2010, 52:218-222.
59. Estecio M.R., Yan P.S., Ibrahim A.E., Tellez C.S., Shen L., Huang T.H., Issa J.P. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res. 2007, 17:1529-1536.
60. Estecio M.R., Yan P.S., Huang T.H., Issa J.P. Methylated CpG island amplification and microarray (MCAM) for high-throughput analysis of DNA methylation. C.S.H. Protoc. 2008, 3. 10.1101/pdb.prot4974.
61. Brunner A.L., Johnson D.S., Kim S.W., Valouev A., Reddy T.E., Neff N.F., Anton E., Medina C., Nguyen L., Chiao E., Oyolu C.B., Schroth G.P., Absher D.M., Baker J.C., Myers R.M. Distinct DNA methylation patterns characterize differentiated human embryonic stem cells and developing human fetal liver. Genome Res. 2009, 19:1044-1056.
62. Colaneri A., Staffa N., Fargo D.C., Gao Y., Wang T., Peddada S.D., Birnbaumer L. Expanded methyl-sensitive cut counting reveals hypomethylation as an epigenetic state that highlights functional sequences of the genome. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:9715-9720.
63. Jia J., Pekowska A., Jaeger S., Benoukraf T., Ferrier P., Spicuglia S. Assessing the efficiency and significance of methylated DNA immunoprecipitation (MeDIP) assays in using in vitro methylated genomic DNA. BMC Res. Notes 2010, 3:240.
64. Weber M., Davies J.J., Wittig D., Oakeley E.J., Haase M., Lam W.L., Schubeler D. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 2005, 37:853-862.
65. Down T.A., Rakyan V.K., Turner D.J., Flicek P., Li H., Kulesha E., Graf S., Johnson N., Herrero J., Tomazou E.M., Thorne N.P., Backdahl L., Herberth M., Howe K.L., Jackson D.K., Miretti M.M., Marioni J.C., Birney E., Hubbard T.J., Durbin R., Tavare S., Beck S. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nat. Biotechnol. 2008, 26:779-785.
66. Pelizzola M., Koga Y., Urban A.E., Krauthammer M., Weissman S., Halaban R., Molinaro A.M. MEDME: an experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment. Genome Res. 2008, 18:1652-1659.
67. Wilson I.M., Davies J.J., Weber M., Brown C.J., Alvarez C.E., MacAulay C., Schubeler D., Lam W.L. Epigenomics: mapping the methylome. Cell Cycle 2006, 5:155-158.
68. Pomraning K.R., Smith K.M., Freitag M. Genome-wide high throughput analysis of DNA methylation in eukaryotes. Methods 2009, 47:142-150.
69. Rauch T.A., Pfeifer G.P. The MIRA method for DNA methylation analysis. Methods Mol. Biol. 2009, 507:65-75.
70. Egger G., Wielscher M., Pulverer W., Kriegner A., Weinhausel A. DNA methylation testing and marker validation using PCR: diagnostic applications. Expert Rev. Mol. Diagn. 2012, 12:75-92.
71. Frommer M., McDonald L.E., Millar D.S., Collis C.M., Watt F., Grigg G.W., Molloy P.L., Paul C.L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:1827-1831.
72. Kristensen L.S., Hansen L.L. PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin. Chem. 2009, 55:1471-1483.
73. Grunau C., Clark S.J., Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. 2001, 29:E65-E71.
74. Hayatsu H., Shiraishi M., Negishi K. Bisulfite modification for analysis of DNA methylation. Curr. Protoc. Nucleic Acid Chem. 2008, 33:6.10.1-6.10.15.
75. Yamamoto N., Nakayama T., Kajita M., Miyake T., Iwamoto T., Kim S.J., Sakai A., Ishihara H., Tamaki Y., Noguchi S. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARbeta2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res. Treat. 2012, 132:165-173.
76. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Blake C., Shibata D., Danenberg P.V., Laird P.W. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28:E32.
77. Lehmann U., Langer F., Feist H., Glockner S., Hasemeier B., Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol. 2002, 160:605-612.
78. Kim J.H., Shin M.H., Kweon S.S., Park M.H., Yoon J.H., Lee J.S., Choi C., Fackler M.J., Sukumar S. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women. Gynecol. Oncol. 2010, 118:176-181.
79. Wojdacz T.K., Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res. 2007, 35:e41.
80. Gonzalgo M.L., Liang G. Methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) for quantitative measurement of DNA methylation. Nat. Protoc. 2007, 2:1931-1936.
81. Zeschnigk M., Bohringer S., Price E.A., Onadim Z., Masshofer L., Lohmann D.R. A novel real-time PCR assay for quantitative analysis of methylated alleles (QAMA): analysis of the retinoblastoma locus. Nucleic Acids Res. 2004, 32:e125.
82. Cottrell S.E., Distler J., Goodman N.S., Mooney S.H., Kluth A., Olek A., Schwope I., Tetzner R., Ziebarth H., Berlin K. A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res. 2004, 32:e10.
83. Xiong Z., Laird P.W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997, 25:2532-2534.
84. Brena R.M., Auer H., Kornacker K., Hackanson B., Raval A., Byrd J.C., Plass C. Accurate quantification of DNA methylation using combined bisulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform. Nucleic Acids Res. 2006, 34:e17.
85. Ronaghi M., Uhlen M., Nyren P. A sequencing method based on real-time pyrophosphate. Science 1998, 281:363-365.
86. Shames D.S., Minna J.D., Gazdar A.F. Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett. 2007, 251:187-198.
87. Tost J., Dunker J., Gut I.G. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 2003, 35:152-156.
88. Dupont J.M., Tost J., Jammes H., Gut I.G. De novo quantitative bisulfite sequencing using the pyrosequencing technology. Anal. Biochem. 2004, 333:119-127.
89. Reinders J., Delucinge Vivier C., Theiler G., Chollet D., Descombes P., Paszkowski J. Genome-wide, high-resolution DNA methylation profiling using bisulfite-mediated cytosine conversion. Genome Res. 2008, 18:469-476.
90. Bibikova M., Le J., Barnes B., Saedinia-Melnyk S., Zhou L., Shen R., Gunderson K.L. Genome-wide DNA methylation profiling using Infinium(R) assay. Epigenomics 2009, 1:177-200.
91. Bibikova M., Barnes B., Tsan C., Ho V., Klotzle B., Le J.M., Delano D., Zhang L., Schroth G.P., Gunderson K.L., Fan J.B., Shen R. High density DNA methylation array with single CpG site resolution. Genomics 2011, 98:288-295.
92. Krueger F., Kreck B., Franke A., Andrews S.R. DNA methylome analysis using short bisulfite sequencing data. Nat. Methods 2012, 9:145-151.
93. Wang L., Sun J., Wu H., Liu S., Wang J., Wu B., Huang S., Li N., Zhang X. Systematic assessment of reduced representation bisulfite sequencing to human blood samples: a promising method for large-sample-scale epigenomic studies. J. Biotechnol. 2012, 157:1-6.
94. Deng J., Shoemaker R., Xie B., Gore A., LeProust E.M., Antosiewicz-Bourget J., Egli D., Maherali N., Park I.H., Yu J., Daley G.Q., Eggan K., Hochedlinger K., Thomson J., Wang W., Gao Y., Zhang K. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat. Biotechnol. 2009, 27:353-360.
95. Qureshi S.A., Bashir M.U., Yaqinuddin A. Utility of DNA methylation markers for diagnosing cancer. Int. J. Surg. 2010, 8:194-198.
96. Schouten J.P., McElgunn C.J., Waaijer R., Zwijnenburg D., Diepvens F., Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002, 30:e57.
97. Ehrich M., Nelson M.R., Stanssens P., Zabeau M., Liloglou T., Xinarianos G., Cantor C.R., Field J.K., van den Boom D. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15785-15790.
98. Radpour R., Haghighi M.M., Fan A.X., Torbati P.M., Hahn S., Holzgreve W., Zhong X.Y. High-throughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidine-specific cleavage mass array on MALDI-TOF silico-chip. Mol. Cancer Res. 2008, 6:1702-1709.
99. Dulaimi E., Hillinck J., Ibanez de Caceres I., Al-Saleem T., Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin. Cancer Res. 2004, 10:6189-6193.
100. Fang F., Turcan S., Rimner A., Kaufman A., Giri D., Morris L.G., Shen R., Seshan V., Mo Q., Heguy A., Baylin S.B., Ahuja N., Viale A., Massague J., Norton L., Vahdat L.T., Moynahan M.E., Chan T.A. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci. Transl. Med. 2011, 3:75ra25.
101. Mirza S., Sharma G., Prasad C.P., Parshad R., Srivastava A., Gupta S.D., Ralhan R. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci. 2007, 81:280-287.
102. Bosviel R., Garcia S., Lavediaux G., Michard E., Dravers M., Kwiatkowski F., Bignon Y.J., Bernard-Gallon D.J. BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. Cancer Epidemiol. 2012, 10.1016/j.canep.2012.02.001.
103. Tew K.D., Townsend D.M. Regulatory functions of glutathione S-transferase P1-1 unrelated to detoxification. Drug Metab. Rev. 2011, 43:179-193.
104. Parrella P. Epigenetic signatures in breast cancer: clinical perspective. Breast Care (Basel) 2010, 5:66-73.
105. Shukla S., Mirza S., Sharma G., Parshad R., Gupta S.D., Ralhan R. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients. Epigenetics 2006, 1:88-93.
106. Matuschek C., Bolke E., Lammering G., Gerber P.A., Peiper M., Budach W., Taskin H., Prisack H.B., Schieren G., Orth K., Bojar H. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Eur. J. Med. Res. 2010, 15:277-286.
107. Widschwendter M., Berger J., Hermann M., Muller H.M., Amberger A., Zeschnigk M., Widschwendter A., Abendstein B., Zeimet A.G., Daxenbichler G., Marth C. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J. Natl. Cancer Inst. 2000, 92:826-832.
108. Jacinto F.V., Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 2007, 22:247-253.
109. Sharma G., Mirza S., Parshad R., Srivastava A., Gupta S.D., Pandya P., Ralhan R. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci. 2010, 87:83-91.
110. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
111. Sharma G., Mirza S., Prasad C.P., Srivastava A., Gupta S.D., Ralhan R. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci. 2007, 80:1873-1881.
112. Woodcock D.M., Linsenmeyer M.E., Doherty J.P., Warren W.D. DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours. Br. J. Cancer 1999, 79:251-256.
113. Reynolds P.A., Sigaroudinia M., Zardo G., Wilson M.B., Benton G.M., Miller C.J., Hong C., Fridlyand J., Costello J.F., Tlsty T.D. Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J. Biol. Chem. 2006, 281:24790-24802.
114. Zurita M., Lara P.C., del Moral R., Torres B., Linares-Fernandez J.L., Arrabal S.R., Martinez-Galan J., Oliver F.J., Ruiz de Almodovar J.M. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer 2010, 10:217.
115. Martinez-Galan J., Torres B., Del Moral R., Munoz-Gamez J.A., Martin-Oliva D., Villalobos M., Nunez M.I., Luna Jde D., Oliver F.J., Ruiz de Almodovar J.M. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol. Ther. 2008, 7:958-965.
116. Pu R.T., Laitala L.E., Alli P.M., Fackler M.J., Sukumar S., Clark D.P. Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod. Pathol. 2003, 16:1095-1101.
117. Umbricht C.B., Evron E., Gabrielson E., Ferguson A., Marks J., Sukumar S. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001, 20:3348-3353.
118. Mirza S., Sharma G., Parshad R., Srivastava A., Gupta S.D., Ralhan R. Clinical significance of Stratifin, ERalpha and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Clin. Biochem. 2010, 43:380-386.
119. Evron E., Dooley W.C., Umbricht C.B., Rosenthal D., Sacchi N., Gabrielson E., Soito A.B., Hung D.T., Ljung B., Davidson N.E., Sukumar S. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001, 357:1335-1336.
120. Lewis S.J., Harbord R.M., Harris R., Smith G.D. Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. J. Natl. Cancer Inst. 2006, 98:1607-1622.
121. Nass S.J., Herman J.G., Gabrielson E., Iversen P.W., Parl F.F., Davidson N.E., Graff J.R. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res. 2000, 60:4346-4348.
122. Graff J.R., Herman J.G., Lapidus R.G., Chopra H., Xu R., Jarrard D.F., Isaacs W.B., Pitha P.M., Davidson N.E., Baylin S.B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995, 55:5195-5199.
123. Nass S.J., Ferguson A.T., El-Ashry D., Nelson W.G., Davidson N.E. Expression of DNA methyl-transferase (DMT) and the cell cycle in human breast cancer cells. Oncogene 1999, 18:7453-7461.
124. Jing F., Yuping W., Yong C., Jie L., Jun L., Xuanbing T., Lihua H. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol. 2010, 31:321-331.
125. Brose K., Bland K.S., Wang K.H., Arnott D., Henzel W., Goodman C.S., Tessier-Lavigne M., Kidd T. Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell 1999, 96:795-806.
126. Yuan W., Zhou L., Chen J.H., Wu J.Y., Rao Y., Ornitz D.M. The mouse SLIT family: secreted ligands for ROBO expressed in patterns that suggest a role in morphogenesis and axon guidance. Dev. Biol. 1999, 212:290-306.
127. Marlow R., Strickland P., Lee J.S., Wu X., Pebenito M., Binnewies M., Le E.K., Moran A., Macias H., Cardiff R.D., Sukumar S., Hinck L. SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium. Cancer Res. 2008, 68:7819-7827.
128. Dallol A., Da Silva N.F., Viacava P., Minna J.D., Bieche I., Maher E.R., Latif F. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res. 2002, 62:5874-5880.
129. Kim G.E., Lee K.H., Choi Y.D., Lee J.S., Lee J.H., Nam J.H., Choi C., Park M.H., Yoon J.H. Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients. Virchows Arch. 2011, 459:383-390.
130. Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 2002, 4:197-201.
131. Issa J.P., Baylin S.B., Belinsky S.A. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res. 1996, 56:3655-3658.
132. Chang H.G., Kim S.J., Chung K.W., Noh D.Y., Kwon Y., Lee E.S., Kang H.S. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene. J. Mol. Med. (Berl) 2005, 83:132-139.
133. Pathiraja T.N., Stearns V., Oesterreich S. Epigenetic regulation in estrogen receptor positive breast cancer - role in treatment response. J. Mammary Gland Biol. Neoplasia 2010, 15:35-47.
134. Dejeux E., Ronneberg J.A., Solvang H., Bukholm I., Geisler S., Aas T., Gut I.G., Borresen-Dale A.L., Lonning P.E., Kristensen V.N., Tost J. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol. Cancer 2010, 9:68.
135. Fackler M.J., Rivers A., Teo W.W., Mangat A., Taylor E., Zhang Z., Goodman S., Argani P., Nayar R., Susnik B., Sukumar S., Khan S.A. Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge. Clin. Cancer Res. 2009, 15:3802-3811.
136. Fiegl H., Millinger S., Mueller-Holzner E., Marth C., Ensinger C., Berger A., Klocker H., Goebel G., Widschwendter M. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 2005, 65:1141-1145.
137. Gobel G., Auer D., Gaugg I., Schneitter A., Lesche R., Muller-Holzner E., Marth C., Daxenbichler G. Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res. Treat. 2011, 130:109-117.
138. Dworkin A.M., Huang T.H., Toland A.E. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin. Cancer Biol. 2009, 19:165-171.
139. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343:1350-1354.
140. Liggett T.E., Melnikov A.A., Marks J.R., Levenson V.V. Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int. J. Cancer 2011, 128:492-499.
141. Meng S., Tripathy D., Frenkel E.P., Shete S., Naftalis E.Z., Huth J.F., Beitsch P.D., Leitch M., Hoover S., Euhus D., Haley B., Morrison L., Fleming T.P., Herlyn D., Terstappen L.W., Fehm T., Tucker T.F., Lane N., Wang J., Uhr J.W. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 2004, 10:8152-8162.
142. Van der Auwera I., Elst H.J., Van Laere S.J., Maes H., Huget P., van Dam P., Van Marck E.A., Vermeulen P.B., Dirix L.Y. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br. J. Cancer 2009, 100:1277-1286.
143. Avraham A., Uhlmann R., Shperber A., Birnbaum M., Sandbank J., Sella A., Sukumar S., Evron E. Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int. J. Cancer 2012, 10.1002/ijc.27526.
144. Krawczyk B., Fabianowska-Majewska K. Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues. Nucleosides Nucleotides Nucleic Acids 2006, 25:1029-1032.
145. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49:243-263.
146. Lapidus R.G., Ferguson A.T., Ottaviano Y.L., Parl F.F., Smith H.S., Weitzman S.A., Baylin S.B., Issa J.P., Davidson N.E. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res. 1996, 2:805-810.
147. Cheng J.C., Yoo C.B., Weisenberger D.J., Chuang J., Wozniak C., Liang G., Marquez V.E., Greer S., Orntoft T.F., Thykjaer T., Jones P.A. Preferential response of cancer cells to zebularine. Cancer Cell 2004, 6:151-158.
148. Chik F., Szyf M. Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis 2011, 32:224-232.
149. Sandhu R., Rivenbark A.G., Coleman W.B. Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b. Breast Cancer Res. Treat. 2012, 131:385-399.
150. Rius M., Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene 2011, 10.1038/onc.2011.601.
151. Chuang J.C., Warner S.L., Vollmer D., Vankayalapati H., Redkar S., Bearss D.J., Qiu X., Yoo C.B., Jones P.A. S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol. Cancer Ther. 2010, 9:1443-1450.
152. Brueckner B., Rius M., Markelova M.R., Fichtner I., Hals P.A., Sandvold M.L., Lyko F. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol. Cancer Ther. 2010, 9:1256-1264.
153. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
154. Billam M., Sobolewski M.D., Davidson N.E. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res. Treat. 2010, 120:581-592.
155. Boothman D.A., Briggle T.V., Greer S. Exploitation of elevated pyrimidine deaminating enzymes for selective chemotherapy. Pharmacol. Ther. 1989, 42:65-88.
156. Issa J.P., Kantarjian H.M. Targeting DNA methylation. Clin. Cancer Res. 2009, 15:3938-3946.
157. Schuebel K., Baylin S. In living color: DNA methyltransferase caught in the act. Nat. Methods 2005, 2:736-738.
158. Hatziapostolou M., Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell. Mol. Life Sci. 2011, 68:1681-1702.
159. Cai F.F., Kohler C., Zhang B., Wang M.H., Chen W.J., Zhong X.Y. Epigenetic therapy for breast cancer. Int. J. Mol. Sci. 2011, 12:4465-4487.
160. Kuck D., Singh N., Lyko F., Medina-Franco J.L. Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation. Bioorg. Med. Chem. 2010, 18:822-829.
161. Segura-Pacheco B., Trejo-Becerril C., Perez-Cardenas E., Taja-Chayeb L., Mariscal I., Chavez A., Acuna C., Salazar A.M., Lizano M., Duenas-Gonzalez A. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res. 2003, 9:1596-1603.
162. Villar-Garea A., Fraga M.F., Espada J., Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003, 63:4984-4989.
163. Duenas-Gonzalez A., Candelaria M., Perez-Plascencia C., Perez-Cardenas E., de la Cruz-Hernandez E., Herrera L.A. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat. Rev. 2008, 34:206-222.
164. Meeran S.M., Ahmed A., Tollefsbol T.O. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin. Epigenetics 2010, 1:101-116.
165. Khan S.I., Aumsuwan P., Khan I.A., Walker L.A., Dasmahapatra A.K. Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome. Chem. Res. Toxicol. 2012, 25:61-73.
166. Feigelson H.S., Jonas C.R., Robertson A.S., McCullough M.L., Thun M.J., Calle E.E. Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol. Biomarkers Prev. 2003, 12:161-164.
167. Stolzenberg-Solomon R.Z., Chang S.C., Leitzmann M.F., Johnson K.A., Johnson C., Buys S.S., Hoover R.N., Ziegler R.G. Folate intake, alcohol use, and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Am. J. Clin. Nutr. 2006, 83:895-904.
168. Sellers T.A., Kushi L.H., Cerhan J.R., Vierkant R.A., Gapstur S.M., Vachon C.M., Olson J.E., Therneau T.M., Folsom A.R. Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology 2001, 12:420-428.
169. Shrubsole M.J., Shu X.O., Li H.L., Cai H., Yang G., Gao Y.T., Gao J., Zheng W. Dietary B vitamin and methionine intakes and breast cancer risk among Chinese women. Am. J. Epidemiol. 2011, 173:1171-1182.
170. Lin J., Lee I.M., Cook N.R., Selhub J., Manson J.E., Buring J.E., Zhang S.M. Plasma folate, vitamin B-6, vitamin B-12, and risk of breast cancer in women. Am. J. Clin. Nutr. 2008, 87:734-743.
171. Kim Y.I. Does a high folate intake increase the risk of breast cancer?. Nutr. Rev. 2006, 64:468-475.
172. Choi S.W., Friso S. Epigenetics: a new bridge between nutrition and health. Adv. Nutr. 2010, 1:8-16.
173. Uekawa A., Katsushima K., Ogata A., Kawata T., Maeda N., Kobayashi K., Maekawa A., Tadokoro T., Yamamoto Y. Change of epigenetic control of cystathionine beta-synthase gene expression through dietary vitamin B12 is not recovered by methionine supplementation. J. Nutrigenet. Nutrigenomics 2009, 2:29-36.
174. Marian C., Tao M., Mason J.B., Goerlitz D.S., Nie J., Chanson A., Freudenheim J.L., Shields P.G. Single nucleotide polymorphisms in uracil-processing genes, intake of one-carbon nutrients and breast cancer risk. Eur. J. Clin. Nutr. 2011, 65:683-689.
175. Ma E., Iwasaki M., Kobayashi M., Kasuga Y., Yokoyama S., Onuma H., Nishimura H., Kusama R., Tsugane S. Dietary intake of folate, vitamin B2, vitamin B6, vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case-control study in Japan. Nutr. Cancer 2009, 61:447-456.
176. Cho E., Holmes M., Hankinson S.E., Willett W.C. Nutrients involved in one-carbon metabolism and risk of breast cancer among premenopausal women. Cancer Epidemiol. Biomarkers Prev. 2007, 16:2787-2790.
177. Jing F., Jun L., Yong Z., Wang Y., Fei X., Zhang J., Hu L. Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker. Oncology 2008, 75:60-66.
178. Molina R., Barak V., van Dalen A., Duffy M.J., Einarsson R., Gion M., Goike H., Lamerz R., Nap M., Soletormos G., Stieber P. Tumor markers in breast cancer - European Group on tumor markers recommendations. Tumour Biol. 2005, 26:281-293.
179. Jeronimo C., Costa I., Martins M.C., Monteiro P., Lisboa S., Palmeira C., Henrique R., Teixeira M.R., Lopes C. Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin. Cancer Res. 2003, 9:3413-3417.
180. Ahuja N., Issa J.P. Aging, methylation and cancer. Histol. Histopathol. 2000, 15:835-842.
181. Aran D., Toperoff G., Rosenberg M., Hellman A. Replication timing-related and gene body-specific methylation of active human genes. Hum. Mol. Genet. 2011, 20:670-680.
182. Lewis C.M., Cler L.R., Bu D.W., Zochbauer-Muller S., Milchgrub S., Naftalis E.Z., Leitch A.M., Minna J.D., Euhus D.M. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin. Cancer Res. 2005, 11:166-172.
183. Vasilatos S.N., Broadwater G., Barry W.T., Baker J.C., Lem S., Dietze E.C., Bean G.R., Bryson A.D., Pilie P.G., Goldenberg V., Skaar D., Paisie C., Torres-Hernandez A., Grant T.L., Wilke L.G., Ibarra-Drendall C., Ostrander J.H., D'Amato N.C., Zalles C., Jirtle R., Weaver V.M., Seewaldt V.L. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol. Biomarkers Prev. 2009, 18:901-914.
184. Yazici H., Terry M.B., Cho Y.H., Senie R.T., Liao Y., Andrulis I., Santella R.M. Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2723-2725.
185. Flanagan J.M., Cocciardi S., Waddell N., Johnstone C.N., Marsh A., Henderson S., Simpson P., da Silva L., Khanna K., Lakhani S., Boshoff C., Chenevix-Trench G. DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am. J. Hum. Genet. 2010, 86:420-433.
186. Barry W.T., Kernagis D.N., Dressman H.K., Griffis R.J., Hunter J.D., Olson J.A., Marks J.R., Ginsburg G.S., Marcom P.K., Nevins J.R., Geradts J., Datto M.B. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J. Clin. Oncol. 2010, 28:2198-2206.
187. Kikuyama M., Takeshima H., Kinoshita T., Okochi-Takada E., Wakabayashi M., Akashi-Tanaka S., Ogawa T., Seto Y., Ushijima T. Development of a novel approach, the epigenome-based outlier approach, to identify tumor-suppressor genes silenced by aberrant DNA methylation. Cancer Lett. 2012, 10.1016/j.canlet.2012.03.016.
188. Ruike Y., Imanaka Y., Sato F., Shimizu K., Tsujimoto G. Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics 2010, 11:137.
189. Weng Y.I., Huang T.H., Yan P.S. Methylated DNA immunoprecipitation and microarray-based analysis: detection of DNA methylation in breast cancer cell lines. Methods Mol. Biol. 2009, 590:165-176.
190. Beck J., Urnovitz H.B., Mitchell W.M., Schutz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol. Cancer Res. 2010, 8:335-342.
191. Korshunova Y., Maloney R.K., Lakey N., Citek R.W., Bacher B., Budiman A., Ordway J.M., McCombie W.R., Leon J., Jeddeloh J.A., McPherson J.D. Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA. Genome Res. 2008, 18:19-29.
192. Glenn T.C. Field guide to next-generation DNA sequencers. Mol. Ecol. Resour. 2011, 11:759-769.
193. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
194. Sturgeon C.M., Duffy M.J., Stenman U.H., Lilja H., Brunner N., Chan D.W., Babaian R., Bast R.C., Dowell B., Esteva F.J., Haglund C., Harbeck N., Hayes D.F., Holten-Andersen M., Klee G.G., Lamerz R., Looijenga L.H., Molina R., Nielsen H.J., Rittenhouse H., Semjonow A., Shih Ie M., Sibley P., Soletormos G., Stephan C., Sokoll L., Hoffman B.R., Diamandis E.P. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem. 2008, 54:e11-e79.
195. Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G., Belinsky S.A. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000, 60:5954-5958.
196. Voso M.T., Scardocci A., Guidi F., Zini G., Di Mario A., Pagano L., Hohaus S., Leone G. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 2004, 103:698-700.
197. Weisenberger D.J., Trinh B.N., Campan M., Sharma S., Long T.I., Ananthnarayan S., Liang G., Esteva F.J., Hortobagyi G.N., McCormick F., Jones P.A., Laird P.W. DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res. 2008, 36:4689-4698.
198. Jing F., Zhang J., Tao J., Zhou Y., Jun L., Tang X., Wang Y., Hai H. Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3 sigma in serum of sporadic breast cancer patients. Onkologie 2007, 30:14-19.
199. Hoque M.O., Feng Q., Toure P., Dem A., Critchlow C.W., Hawes S.E., Wood T., Jeronimo C., Rosenbaum E., Stern J., Yu M., Trink B., Kiviat N.B., Sidransky D. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J. Clin. Oncol. 2006, 24:4262-4269.
200. Brooks J.D., Cairns P., Shore R.E., Klein C.B., Wirgin I., Afanasyeva Y., Zeleniuch-Jacquotte A. DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study. Cancer Epidemiol. 2010, 34:717-723.
201. Taback B., Giuliano A.E., Lai R., Hansen N., Singer F.R., Pantel K., Hoon D.S. Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. Ann. N. Y. Acad. Sci. 2006, 1075:211-221.
202. Tan S.H., Ida H., Lau Q.C., Goh B.C., Chieng W.S., Loh M., Ito Y. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol. Rep. 2007, 18:1225-1230.
203. Papadopoulou E., Davilas E., Sotiriou V., Georgakopoulos E., Georgakopoulou S., Koliopanos A., Aggelakis F., Dardoufas K., Agnanti N.J., Karydas I., Nasioulas G. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. N. Y. Acad. Sci. 2006, 1075:235-243.
204. Ahmed I.A., Pusch C.M., Hamed T., Rashad H., Idris A., El-Fadle A.A., Blin N. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA. Cancer Genet. Cytogenet. 2010, 199:96-100.
205. Hu X.C., Wong I.H., Chow L.W. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications. Oncol. Rep. 2003, 10:1811-1815.
206. Lee M.N., Tseng R.C., Hsu H.S., Chen J.Y., Tzao C., Ho W.L., Wang Y.C. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin. Cancer Res. 2007, 13:832-838.
207. Amin K.S., Banerjee P.P. The cellular functions of RASSF1A and its inactivation in prostate cancer. J. Carcinog. 2012, 11:3.
208. Ha Y.S., Jeong P., Kim J.S., Kwon W.A., Kim I.Y., Yun S.J., Kim G.Y., Choi Y.H., Moon S.K., Kim W.J. Tumorigenic and prognostic significance of RASSF1A expression in low-grade (WHO Grade 1 and Grade 2) nonmuscle-invasive bladder cancer. Urology 2012, 10.1016/j.urology.2012.01.042.
209. Kim J.S., Chae Y., Ha Y.S., Kim I.Y., Byun S.S., Yun S.J., Kim W.J. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer. Clin. Genitourin. Cancer 2012, 10.1016/j.clgc.2011.12.003.
210. Esteller M., Sparks A., Toyota M., Sanchez-Cespedes M., Capella G., Peinado M.A., Gonzalez S., Tarafa G., Sidransky D., Meltzer S.J., Baylin S.B., Herman J.G. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000, 60:4366-4371.
211. Virmani A.K., Rathi A., Sathyanarayana U.G., Padar A., Huang C.X., Cunnigham H.T., Farinas A.J., Milchgrub S., Euhus D.M., Gilcrease M., Herman J., Minna J.D., Gazdar A.F. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin. Cancer Res. 2001, 7:1998-2004.
212. Piperi C., Themistocleous M.S., Papavassiliou G.A., Farmaki E., Levidou G., Korkolopoulou P., Adamopoulos C., Papavassiliou A.G. High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome. Mol. Med. 2010, 16:1-9.
213. Su C., Ren Z.J., Wang F., Liu M., Li X., Tang H. PIWIL4 regulates cervical cancer cell line growth and is involved in down-regulating the expression of p14ARF and p53. FEBS Lett. 2012, 586:1356-1362.
214. Costello J.F., Berger M.S., Huang H.S., Cavenee W.K. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 1996, 56:2405-2410.
215. Garcia M.J., Castrillo J.M., Granizo J.J., Cazorla A., Rivas C. Clinicopathological correlation, p16-p15 methylation status and outcome predictors in anaplastic large cell lymphoma. Br. J. Haematol. 2002, 119:877-878.
216. Ng M.H., Chung Y.F., Lo K.W., Wickham N.W., Lee J.C., Huang D.P. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997, 89:2500-2506.
217. Ushijima T. Epigenetic field for cancerization. J. Biochem. Mol. Biol. 2007, 40:142-150.
218. Zerrouqi A., Pyrzynska B., Febbraio M., Brat D.J., Van Meir E.G. P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3. J. Clin. Invest. 2012, 122:1283-1295.
219. Dim D.C., Jiang F., Qiu Q., Li T., Darwin P., Rodgers W.H., Peng H.Q. The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration. Diagn. Cytopathol. 2011, 10.1002/dc.21684.
220. Okumura H., Kita Y., Yokomakura N., Uchikado Y., Setoyama T., Sakurai H., Omoto I., Matsumoto M., Owaki T., Ishigami S., Natsugoe S. Nuclear expression of 14-3-3 sigma is related to prognosis in patients with esophageal squamous cell carcinoma. Anticancer Res. 2010, 30:5175-5179.
221. Pei H.P., Ge H., Jiang R., Zhu H. [Expression and clinical significance of 14-3-3 sigma and heat shock protein 27 in colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 2010, 13:213-215.
222. Grau E., Martinez F., Orellana C., Canete A., Yanez Y., Oltra S., Noguera R., Hernandez M., Bermudez J.D., Castel V. Epigenetic alterations in disseminated neuroblastoma tumour cells: influence of TMS1 gene hypermethylation in relapse risk in NB patients. J. Cancer Res. Clin. Oncol. 2010, 136:1415-1421.
223. Ramachandran K., Miller H., Gordian E., Rocha-Lima C., Singal R. Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity. Anticancer Res. 2010, 30:3919-3925.
224. Igawa T., Sato Y., Takata K., Fushimi S., Tamura M., Nakamura N., Maeda Y., Orita Y., Tanimoto M., Yoshino T. Cyclin D2 is overexpressed in proliferation centers of chronic lymphocytic leukemia/small lymphocytic lymphoma. Cancer Sci. 2011, 102:2103-2107.
225. Bartholow T.L., Becich M.J., Chandran U.R., Parwani A.V. Immunohistochemical staining of slit2 in primary and metastatic prostatic adenocarcinoma. Transl. Oncol. 2011, 4:314-320.
226. Dickinson R.E., Fegan K.S., Ren X., Hillier S.G., Duncan W.C. Glucocorticoid regulation of SLIT/ROBO tumour suppressor genes in the ovarian surface epithelium and ovarian cancer cells. PLoS One 2011, 6:e27792.
227. Jin J., You H., Yu B., Deng Y., Tang N., Yao G., Shu H., Yang S., Qin W. Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas. Biochem. Biophys. Res. Commun. 2009, 379:86-91.
228. Li L.C., Chui R., Nakajima K., Oh B.R., Au H.C., Dahiya R. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res. 2000, 60:702-706.
229. Mori T., Martinez S.R., O'Day S.J., Morton D.L., Umetani N., Kitago M., Tanemura A., Nguyen S.L., Tran A.N., Wang H.J., Hoon D.S. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res. 2006, 66:6692-6698.
230. Ren Y., Liu X., Ma D., Feng Y., Zhong N. Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. Cancer Genet. Cytogenet. 2007, 175:107-116.